Reduced‐dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study-Reference-Cited by-同舟云学术

Reduced‐dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study

Published:2019-10-16 Issue:12 Volume:59 Page:3721-3726
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Gutiérrez‐Aguirre Cesar Homero¹^ORCID,Alvarado‐Navarro Dalila Marisol¹,Palomares‐Leal Alain¹,Mejía‐Jaramillo Gerardo¹,Salazar‐Riojas Rosario¹,León Andrés Gómez‐De¹,Colunga‐Pedraza Perla Rocío¹,Sotomayor‐Duque Guillermo¹,Jaime‐Pérez José Carlos¹^ORCID,Cantú‐Rodríguez Olga Graciela¹,Carmen Tarín‐Arzaga Luz¹,Flores‐Jiménez Juan Antonio¹,Gómez‐Almaguer David¹

Affiliation:

1. Hematology Service, Hospital Universitario Dr. José Eleuterio GonzálezUniversidad Autónoma de Nuevo León Monterrey Mexico

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.15547

Reference27 articles.

1. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy

2. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone

3. Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers